Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Survival rates for allografts have improved over the last 2 decades, yet failing allografts remains a challenge in the field of transplant. The risks of mortality and morbidity associated with failed allografts are compounded by infectious complications and metabolic abnormalities, emphasizing the need for a standardized approach to management. Management of failing allografts lacks consensus, highlighting the need for unified protocols to guide treatment protocols and minimize risks with postdialysis initiation. The decision to wean off immunosuppression depends on various factors, including living donor availability and infectious risks, necessitating improved coordination of care and a standard guideline. Treatment of failed pancreas focuses on glycemic control, with insulin as the mainstay, while considering surgical interventions such as graft pancreatectomy in advanced symptomatic cases. Navigating the complexities of failed allograft management demands a multidisciplinary approach and standardized stepwise protocol. Addressing the gaps in management plans for failing allografts and employing a systematic approach to transplant decisions will enhance patient outcomes and facilitate informed decision-making.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1053/j.akdh.2024.07.001 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Impact of low-level pretransplant donor-specific antibodies detected by the Luminex platform on acute rejection and long-term graft survival.
World J Transplant
September 2025
Department of Pathology, Sindh Institute of Urology and Transplantation, Karachi 74200, Sindh, Pakistan.
Background: The Luminex platform, where beads are coated with single human leukocyte antigens (HLA), detects HLA antibodies with higher sensitivity and specificity compared to complement-dependent cytotoxicity (CDC) assay and flow cross-match (FCXM). The clinical significance of donor-specific antibodies (DSAs) detected by this method is still under investigation.
Aim: To report the impact of low-level pretransplant DSAs detected by the Luminex platform on the rates of acute rejection (AR), allograft function, and long-term graft survival.
An Optimized Platform Overcomes Excessive Tumor Immune Rejection Induced by the CRISPR/Cas9 Lentiviral System.
Cancer Res
August 2025
Fudan University, Shanghai, China.
The CRISPR/Cas9 lentiviral system has emerged as a powerful tool for gene knockout in cancer immunology research. However, the persistent expression of exogenous elements, such as Cas9 and resistance markers, often triggers excessive tumor immune rejection. This can lead to prolonged experimental timelines, increased data variability, biased outcomes, and even experimental failures.
View Article and Find Full Text PDFAltered Immune Profiles in Non-Failing Heart Donors With Induced Long QT Syndrome: A Potential Risk Factor for Cardiac Allograft Vasculopathy.
Clin Transplant
August 2025
Department of Cardiothoracic Vascular Surgery, People's Hospital of Deyang City, Deyang, Sichuan, P.R. China.
Introduction: Cardiac allograft vasculopathy (CAV) develops more aggressively in recipients of hearts from brain-dead (BD) donors with induced long QT syndrome (iLQTS), yet the underlying mechanisms remain poorly understood. In this study, we employ a multi-omics and experimental framework to explore the role of neuro-immune interactions in non-failing donor hearts affected by iLQTS.
Methods: Single-nuclei RNA sequencing (snRNA-seq) compared four iLQTS and four non-arrhythmic non-failing donor hearts.
Minimally Invasive Posterior SI Joint Fusion with a Novel Cortical Allograft: Real-World, Long-Term, Outcomes from a Large, Multisite US Cohort.
Orthop Res Rev
August 2025
Department of Anesthesiology and Pain Medicine, The University of Kansas Medical Center, Kansas City, KS, USA.
Purpose: Sacroiliac (SI) joint dysfunction accounts for 15% to 30% of reported low back pain. Primary treatments of SI joint dysfunction include medications, bracing, physical therapy, injections, and ablations. When primary non-surgical treatments are unsuccessful, fusion or stabilization may be considered.
View Article and Find Full Text PDFHaploidentical Hematopoietic Cell Transplantation With Post-Transplant Cyclophosphamide for Pediatric Chronic Active Epstein-Barr Virus Infection.
Pediatr Transplant
September 2025
Children's Cancer Center, National Center for Child Health and Development, Tokyo, Japan.
Background: Hematopoietic cell transplantation (HCT) is the only curative treatment for chronic active Epstein-Barr virus infection (CAEBV). While HCT is needed at the appropriate time, there are sometimes difficulties in securing an appropriate donor, making HLA haploidentical donor an alternative option. Recently, post-transplant cyclophosphamide (PTCy) has rapidly gained popularity as a safe graft-versus-host disease (GVHD) prevention strategy for HCT from HLA haploidentical donors; however, there are only a few reports of its use for CAEBV.
View Article and Find Full Text PDF